register

News - Biotechnology

Merck and Microsoft partnerships support Australian-developed COVID-19 vaccine

Health Industry Hub | August 31, 2020 |

Biotech News: COVAX-19 is the first Australian-developed COVID-19 vaccine to pass phase I clinical trials in Australia successfully. Phase II clinical trials are set to begin in September 2020.

Professor Nikolai Petrovsky is the Director of Endocrinology at Flinders Medical Centre, a Professor in the School of Medicine at Flinders University and the founder of Vaxine Pty Ltd, an Adelaide-based biotechnology company specialising in pandemic vaccine design.

COVAX-19 vaccine comprises a recombinant spike protein antigen formulated with Vaxine’s proprietary Advax adjuvant, which drives a potent T cell and neutralising antibody response against the target virus.

The Microsoft AI and Azure cloud capabilities will help the company accelerate clinical testing of its COVAX-19 vaccine.

“Large international Phase III vaccine trials are extraordinarily complex and generate vast amounts of data that needs to be efficiently processed”, says Vaxine Research Director, Flinders University Professor Nikolai Petrovsky.

“Supported by Microsoft technology, we aim to collect and analyse the COVAX-19 trial data in real time, rather than waiting until the end of the trial before seeing if the vaccine is working, which is the traditional process.”

Merck Life Sciences, Managing Director, Rebecca Lee, conducted a recent Q&A video interview with Professor Nikolai Petrovsky.

Join 22,000+
industry professionals
in accessing the latest 
industry news, scientific insights & engaging professional development 
content from
Health Industry HubTM, 
the ONLY one-stop-hub
connecting Australia’s 
Pharma, MedTech & Biotech
industry professionals. Register now.

Merck has a long-standing relationship with Sypharma and Vaxine for more than 10 years, supporting the manufacture of Advax adjuvants with manufacturing solutions, single-use, filtration products and process development expertise.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.